Ultrasonically assisted dermal or transdermal delivery substance preparation
OwnerBruce Reddinginventor
Life of this patent
Estimating the term…
Abstract
A method for improving transdermal delivery of an active ingredient in a formulation made in accordance with a dibasic sodium phosphate containing formula responsively to insonification thereof, including: reducing the amount of dibasic sodium phosphate in the formula to provide a reduced dibasic sodium phosphate formula; and, making a formulation in accordance with the reduced dibasic sodium phosphate formula.
Claims14
A method for improving transdermal delivery of an active ingredient in a formulation made in accordance with a dibasic sodium phosphate containing formula responsively to insonification thereof, comprising:
- reducing the amount of dibasic sodium phosphate in the formula to provide a reduced dibasic sodium phosphate formula;
- and,
- making a formulation in accordance with the reduced dibasic sodium phosphate formula.
A method for improving transdermal delivery of an active ingredient in a formulation made in accordance with an excipient containing formula, wherein said excipient includes at least one component having a specific gravity of at least around 1.67, responsively to insonification thereof, comprising:
- reducing the amount of excipient component having a specific gravity of at least around 1.67 to provide a second formula;
- and,
- making a formulation in accordance with the second formula.
A method for classifying the predicted suitability of a substance for ultrasonically induced transdermal delivery into a patient comprising:
- determining if the substance contains dibasic sodium phosphate;
- and,
- if it does, classifying the substance in a first class;
- and,
- if it does not, classifying the substance in a second class;
- wherein, said first class is associated with substances having a relatively high predicted transdermal delivery rate, and said second class is associated with substances having a relatively low predicted transdermal delivery rate.
A method for classifying the predicted suitability of a substance for ultrasonically induced transdermal delivery into a patient comprising:
- determining if the substance contains an excipient component having a specific gravity of at least around 1.67;
- and,
- if it does, classifying the substance in a first class;
- and,
- if it does not, classifying the substance in a second class;
- wherein, said first class is associated with substances having a relatively high predicted transdermal delivery rate, and said second class is associated with substances having a relatively low predicted transdermal delivery rate.
Dependencies are inferred from the claim text.